Plejdrup Hansen Malene, Høye Sigurd, Hedin Katarina
Center for General Practice, Aalborg University, Aalborg, Denmark.
Research unit for General Practice, Institute of Public Health, University of Southern Denmark, Odense, Denmark.
Scand J Prim Health Care. 2025 Mar;43(1):205-208. doi: 10.1080/02813432.2024.2422441. Epub 2024 Nov 4.
During recent years, the world-including Scandinavia-has experienced significant challenges with shortages of antibiotics. In Scandinavia, phenoxymethylpenicillin is recommended as first-line antibiotic treatment for most acute respiratory tract infections (ARTIs). However, the Scandinavian countries each constitute rather small markets for phenoxymethylpenicillin. The aim of this discussion paper is to enlighten the differences in Scandinavian ARTI antibiotic treatment recommendations. This information is fundamental for exploring the potential of harmonizing treatment recommendations in Denmark, Norway and Sweden-to help ensure sufficient future supply of phenoxymethylpenicillin.
Information from national ARTI antibiotic treatment recommendations from respectively Denmark, Norway and Sweden has been collated.
Several discrepancies exist in recommendations. Adult dosage varies from a minimum of 660 mg x 4 (Denmark) to a maximum of 2000 mg × 3 (Sweden). Within Norway and Sweden, variations in recommended dosage also exist between the different types of ARTIs. A main challenge is that the tablet strengths recommended, and available on the market in the three countries, differs.Also, antibiotic treatment durations vary significantly between countries and infections treated-from five to 10 days of treatment.
In the capacity of a well-established network for antibiotic stewardship, we have enlightened the differences in Scandinavian ARTI antibiotic treatment recommendations. This paper is the first step moving forward to scrutinizing the potential for harmonizing recommendations for Denmark, Norway and Sweden-to help ensure continued supply of phenoxymethylpenicillin for use within the Scandinavian countries.
近年来，包括斯堪的纳维亚半岛在内的全世界都面临着抗生素短缺的重大挑战。在斯堪的纳维亚半岛，苯氧甲基青霉素被推荐作为大多数急性呼吸道感染（ARTIs）的一线抗生素治疗药物。然而，斯堪的纳维亚各国对苯氧甲基青霉素而言，各自构成的市场规模都相当小。本讨论文件的目的是阐明斯堪的纳维亚半岛急性呼吸道感染抗生素治疗建议的差异。这些信息对于探索丹麦、挪威和瑞典统一治疗建议的可能性至关重要，有助于确保未来苯氧甲基青霉素的充足供应。
整理了分别来自丹麦、挪威和瑞典的国家急性呼吸道感染抗生素治疗建议的信息。
建议中存在若干差异。成人剂量从最低660毫克×4（丹麦）到最高2000毫克×3（瑞典）不等。在挪威和瑞典内部，不同类型的急性呼吸道感染之间在推荐剂量上也存在差异。一个主要挑战是，这三个国家推荐的片剂规格以及市场上可买到的片剂规格各不相同。此外，各国之间以及所治疗的感染类型之间，抗生素治疗疗程差异显著，从5天到10天不等。
作为一个成熟的抗生素管理网络，我们阐明了斯堪的纳维亚半岛急性呼吸道感染抗生素治疗建议的差异。本文是迈向审视丹麦、挪威和瑞典统一建议可能性的第一步，有助于确保斯堪的纳维亚国家持续供应苯氧甲基青霉素以供使用。
